For metastatic prostate cancer, initial treatments involving diethylstilbestrol or LH-RH agonists have proven effective in reducing pain and improving ambulatory status in 40 to 70 percent of patients. This evidence concerns the gene GNRH1 and metastatic prostate carcinoma.